Special Drug Use-results Survey for Long-term Use (Fostamatinib)
- Registration Number
- NCT06757257
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Brief Summary
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
- Detailed Description
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 149
Inclusion Criteria
- Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description fostamatinib treatmented fostamatinib -
- Primary Outcome Measures
Name Time Method Adverse events 18 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fostamatinib's SYK inhibition in chronic ITP pathogenesis?
How does fostamatinib compare to TPO-receptor agonists in long-term ITP management for Japanese patients?
Which biomarkers correlate with fostamatinib response in NCT06757257 chronic ITP cohort?
What are the long-term hepatotoxicity risks of fostamatinib in Kissei's ITP observational study?
How does fostamatinib's efficacy in Japanese ITP patients compare to global trials of SYK inhibitors?
Trial Locations
- Locations (1)
Research site
🇯🇵Tokyo And Japanese Other Cities, Japan